Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Toripalimab Versus Placebo Combined With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: a Multicenter, Randomized, Placebo-controlled, Double-blind, Phase 3 Trial

NCT06712888 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06712888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Toripalimab Versus Placebo Combined With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: a Multicenter, Randomized, Placebo-controlled, Double-blind, Phase 3 Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 17, 2025
Completion date
November 26, 2030
Enrollment
466 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma (npc)